NervGen Pharma Corp. (NGENF) Research

NervGen Pharma Corp., including its affiliated entities, is focused on discovering, advancing, and bringing to market pharmaceutical solutions designed to address medical conditions arising from damage to the nervous system. Their primary experimental compound, NVG-291, is currently undergoing Phase 1 clinical trials to assess its potential effectiveness for spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. The company also maintains a licensing partnership with Case Western Reserve University, enabling them to research, further develop, and commercialize a patented technology that shows therapeutic promise for SCI and other conditions linked to nerve damage. Established in 2017, NervGen Pharma Corp. operates from its headquarters in Vancouver, Canada.

Market snapshot

Symbol
NGENF
Price
$3.95
Day change
-2.47%
Market cap
$407.9M
P/E ratio
-8.54x
52-week range
1.5-6.3
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Brii Biosciences Limited (BRIBF)
  • Botanix Pharmaceuticals Limited (BXPHF)
  • BICO Group AB (publ) (CLLKF)
  • Genfit S.A. (GNFTF)
  • Innate Pharma S.A. (IPHYF)
  • JW (Cayman) Therapeutics Co. Ltd (JWCTF)
  • Molecular Partners AG (MLLCF)
  • NDT Pharmaceuticals Inc. (NDTP)

Open NervGen Pharma Corp. (NGENF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.